K. Vandormael
MSD (Belgium)(BE)
Publications by Year
Research Areas
Lipoproteins and Cardiovascular Health, Cancer Immunotherapy and Biomarkers, Health Systems, Economic Evaluations, Quality of Life, Pharmaceutical Economics and Policy, Bone health and osteoporosis research
Most-Cited Works
- → Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study(1999)594 cited
- → Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal‐salt diet(2002)158 cited
- → Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study(2009)68 cited
- → The Effect of Alendronate on Bone Mass After Distal Forearm Fracture(2000)64 cited
- → Comparison of rizatriptan and other triptans on stringent measures of efficacy(2001)47 cited
- → Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease(2005)46 cited
- → Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia(2010)41 cited
- → Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study(2008)33 cited
- → PATIENT SATISFACTION WITH RIZATRIPTAN VERSUS OTHER TRIPTANS: DIRECT HEAD‐TO‐HEAD COMPARISONS(2001)14 cited
- Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy(2003)